Figure 2.

The impact of TKI therapy on primary end points of relapse-free survival and cumulative incidence of relapse. Relapse-free survival (A) was assessed in all 7 studies at 18–59 months follow-up. The overall pooled RR showed significantly better relapse-free survival after TKI therapy, being 0.48 (95% CI, 0.37–0.61; P < 0.001) with no relevant heterogeneity (I² = 0%). Subgroup analyses showed no significant difference in outcome between midostaurin and sorafenib (P = 0.21). Incidence of relapse (B) was assessed in six studies. The overall pooled RR showed significantly reduced incidence of relapse, being 0.35 (95% CI, 0.23–0.51; P < 0.001) in favor of the TKI therapy with no relevant heterogeneity (I² = 0%). Subgroup analyses showed no significant difference in outcome between midostaurin and sorafenib (P = 0.72).